---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-241951"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:24:53.259430+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Climb Bio reports long-term Phase 1b data for budoprutug; up to 3-year proteinuria control

## Summary
- Abstract published for budoprutug (anti-CD19 mAb) showing durable proteinuria control up to 3 years in four PMN patients.
- Three of four patients required no further immunosuppressive treatment after up to 4 doses.
- No treatment-related adverse events grade 3 or higher observed in the Phase 1b trial (NCT04652570).
- Data support continued development of budoprutug for B-cell mediated diseases.
- Company remains focused on advancing its pipeline; risks include clinical and regulatory uncertainties.

## SEC filing metadata
- accession: 0001193125-25-241951
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312525241951/0001193125-25-241951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312525241951/d34212d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-241951
- JSON: https://secwatch.observer/filing/0001193125-25-241951.json
- Plain text: https://secwatch.observer/filing/0001193125-25-241951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.